Article Sidebar
Views PDF: 79
RESULTS OF TREATMENT OF LOW GRADE SEROUS OVARIAN CANCER IN K HOSPITAL
Main Article Content
Abstract
Objective: To identify the clinical characteristics, the laboratory characteristics, the result of treatment, and the prognostic factors of low grade seours ovarian cancer Patients: The patients was diagnosed low grade serous ovarian cancer and treated at Vietnam National Cancer Hospital from January 2015 to novembre. Method: Retrospective combined prospective study, convenience sampling. Results: We collected 35 patients who were eligible for study. The average age at diagnosis was 47,1. Rate of symtomatic patient was 80,0%, the main presenting symptom was bdominal pain (57,1%), 85,7% patients had elevated CA 12-5 befỏe treatment. The rate of stage IIIC was 37,1%. The five-year overall survival rate was 84,5, the five-year disease free survival rate was 73,6%. The stage of disease was the main prognostic factor. Conclusion: Low grade serous ovarian cancer shows distinct features compared to other epithelial ovarian cancers. The majority of patients with early stage had excellent survival
Article Details
References
2. Plaxe SC. Epidemiology of low-grade serous ovarian cancer. American Journal of Obstetrics and Gynecology. 2008;198(4):459.e1-459.e9. doi:10.1016/j.ajog.2008.01.035
3. Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma...: Obstetrics & Gynecology. Accessed October 16, 2023. https://journals.lww. com/greenjournal/abstract/2006/08000/clinical_behavior_of_stage_ii_iv_low_grade_serous.19.aspx
4. Gershenson DM, Bodurka DC, Lu KH, et al. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015;33(24):2675-2682. doi:10.1200/JCO.2015.61.0873
5. Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S. Symptoms of ovarian cancer11We thank V. Leary, RN, and T. Serkin for special contributions to data collection and data analysis, respectively, and R. Portenoy, MD, for consultation and advice on symptoms. Obstetrics & Gynecology. 2001;98(2):212-217. doi:10.1016/S0029-7844(01)01457-0
6. Wohlmuth C, Djedovic V, Kjaer SK, et al. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis. Cancers (Basel). 2022;14(8): 1954. doi:10.3390/ cancers14081954
7. Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess. 2000;4(17):1-113.